Outline of patents

Grant Thornton awarded patent for innovative technology in cta.x — an app for rapid, automated controls testing

Retrieved on: 
Thursday, June 10, 2021
Banking, Technology, Accounting, Professional services, Public policy, Government, Small business, Security, White House, Federal Government, State, Local, Software, Networks, Legal, Insurance, Human resources, Data management, Finance, Consulting, Intellectual property law, Service companies, Intellectual property organizations, Grant Thornton International, Grant Thornton LLP, Patent application, Patent, Thornton, Innovation, United States Patent and Trademark Office, Outline of patents

Grant Thornton LLP has been awarded a patent by the U.S. Patent and Trademark Office for innovations related to the firms controls-test automation app, cta.x.

Key Points: 
  • Grant Thornton LLP has been awarded a patent by the U.S. Patent and Trademark Office for innovations related to the firms controls-test automation app, cta.x.
  • The cta.x app automates and integrates controls testing by taking existing assurance processes and applying them to the full population of procedures and policies governing controls.
  • Beyond the current patent, Grant Thornton has patent applications pending for additional innovations related to the cta.x app and the firms other new technologies.
  • Grant Thornton refers to Grant Thornton LLP, the U.S. member firm of Grant Thornton International Ltd (GTIL).

Immervision Wins Patent Challenge Against LG Electronics

Retrieved on: 
Tuesday, June 1, 2021
Software, Photography, Audio, Video, Hardware, Data management, Consumer electronics, Technology, Mobile, Wireless, Intellectual property law, Apple Inc. litigation, Monopoly, Patent, United States patent law, Patent law, Outline of patents, Patent troll

Immervision, inventor of wide-angle optical design with distortion control and leader in designing advanced vision systems, today announced it has successfully defended its patent against challenges made by LG Electronics.

Key Points: 
  • Immervision, inventor of wide-angle optical design with distortion control and leader in designing advanced vision systems, today announced it has successfully defended its patent against challenges made by LG Electronics.
  • In November 2019, LG petitioned the Patent Trial and Appeal Board, challenging the validity of one of Immervisions key patents (U.S. Patent No.
  • In 2018, Immervision filed a civil complaint against LG for patent infringement over several Smartphone models with wide-angle camera technology.
  • LG responded by challenging the validity of Immervisions patent at the United States Patent and Trademark Office.

GTT Group Releases 1st Quarter Patent Transaction Market Report (PTMR)

Retrieved on: 
Friday, May 21, 2021
Intangible assets, Monopoly, Patent, Patent law, Outline of patents

b'PORTLAND, Ore., May 21, 2021 /PRNewswire-PRWeb/ -- Global Technology Transfer Group, Inc. (GTT Group), a world leader in strategic patent analysis and patent transaction services, released its First Quarter 2021 Patent Transaction Market Report (PTMR) this morning.

Key Points: 
  • b'PORTLAND, Ore., May 21, 2021 /PRNewswire-PRWeb/ -- Global Technology Transfer Group, Inc. (GTT Group), a world leader in strategic patent analysis and patent transaction services, released its First Quarter 2021 Patent Transaction Market Report (PTMR) this morning.
  • The report includes the Patent Market Index (PMI) and the Patent Licensing Index (PLI).\nThe first quarter PMI grew significantly, ultimately reaching a four-year peak.
  • The quarterly report also provides insight regarding recent filing trends in emerging and disruptive technology areas.\nThe Patent Market Index (PMI) tracks patent transaction activity and is reported quarterly in the Patent Transaction Market Report (PTMR).
  • The Patent Licensing Index (PLI) tracks publicly traded patent licensing companies and is also reported quarterly in the PTMR.\nAbout Global Technology Transfer Group, Inc.\nGlobal Technology Transfer Group, Inc. is a patent transaction advisory & consultancy firm.

Patent for ColdZyme approved in Japan

Retrieved on: 
Friday, May 21, 2021
Intellectual property law, Countries, Government, European Patent Organisation, Patent law, Patent, European Patent Office, European Patent Convention, Term of patent, Outline of patents

b'STOCKHOLM, May 21, 2021 /PRNewswire/ -- The Japanese patent authority has granted Enzymatica\'s patent for the cod enzyme that is a key component of Enzymatica\'s cold spray ColdZyme for the Japanese market.

Key Points: 
  • b'STOCKHOLM, May 21, 2021 /PRNewswire/ -- The Japanese patent authority has granted Enzymatica\'s patent for the cod enzyme that is a key component of Enzymatica\'s cold spray ColdZyme for the Japanese market.
  • Corresponding patent was granted by the European Patent Office, EPO, in the spring of 2020.\nEnzymatica has developed an improved cod enzyme formulation for ColdZyme, for which new patent applications were globally filed in 2016.
  • The new patent prolongs the protection for ColdZyme and other Enzymatica products based on the same technology platform for another 15 years.
  • This is a major strengthening of the Enzymatica patent portfolio and represents a significant milestone for the continuous commercialization of the company\'s key products.\n"Having the new patent also granted in Japan, we will have another large market, besides Europe and Russia, that will provide ColdZyme with a long-term patent protection.

Cannabics Pharmaceuticals Receives Patent "Notice of Allowance" From The Mexican Patent and Trademark Office (IMPI)

Retrieved on: 
Thursday, May 6, 2021
Intellectual property law, European Patent Organisation, Patent law, European Patent Office, Patent application, Patent, Outline of patents, Patent prosecution

The decision of the Mexican patent authority follows the European Patent Office (EPO) "Intention to Grant a European Patent"notice to the company from October 2020, concerning the same patent application.\nEyal Barad, Cannabics Pharmaceuticals\' co-founder and CEO commented: "This patent application is a great example of Cannabics\'s innovative and novel approach to the drug discovery process in our field.

Key Points: 
  • The decision of the Mexican patent authority follows the European Patent Office (EPO) "Intention to Grant a European Patent"notice to the company from October 2020, concerning the same patent application.\nEyal Barad, Cannabics Pharmaceuticals\' co-founder and CEO commented: "This patent application is a great example of Cannabics\'s innovative and novel approach to the drug discovery process in our field.
  • The patent was already granted in Israel and in South Africa, and we have been notified of intention to grant in Europe and now also in Mexico.
  • This opens many interesting opportunities for the company in these markets, which we intend to develop and grow.
  • We undertake no duty to update any forward-looking statement or any information contained in this press release or other public disclosures at any time.

Tauriga Sciences, Inc. Converts its U.S. Provisional Patent Application (Filed on March 17, 2020) to a U.S. Non-Provisional Patent Application

Retrieved on: 
Monday, March 22, 2021
United States patent law, Monopoly, Patent law, Provisional application, Patent application, Chewing gum, Patent, Term of patent in the United States, Business law, Outline of patents

Provisional Patent Application (filed on March 17, 2020) to a U.S. Non-Provisional Patent Application.

Key Points: 
  • Provisional Patent Application (filed on March 17, 2020) to a U.S. Non-Provisional Patent Application.
  • This Non-Provisional Patent Application relates to the Companys proposed Pharmaceutical Cannabinoid Chewing Gum Delivery System being developed to treat: Nausea Derived from Active Chemotherapy Treatment.
  • Also on March 17, 2021, to enhance its existing intellectual property (IP) portfolio, the Company filed an additional U.S.
  • On March 18, 2020, the Company announced that it had filed a provisional U.S. patent application covering its pharmaceutical grade version of Tauri-Gum.

KitoTech Medical Announces New U.S. Patent Granted on Its microMend® Wound Closure Products

Retrieved on: 
Thursday, March 18, 2021
Intangible assets, Monopoly, Patent, Outline of patents

The patent is directed at key features of the company's microMend wound closure products that are based on the company's proprietary Microstaple technology.

Key Points: 
  • The patent is directed at key features of the company's microMend wound closure products that are based on the company's proprietary Microstaple technology.
  • KitoTech also has an issued patent in Europe and a newly granted patent in Japan on its microMend products.
  • The new patent expands our IP to protect novel aspects of the products that are essential for optimal wound closure.
  • KitoTech Medical is a medical device company spun out of the University of Washington that is using its patented Microstaples Technology platform to develop and commercialize products for wound closure and wound care.

AgJunction Awarded Three More Precision Ag Patents

Retrieved on: 
Wednesday, March 17, 2021
Monopoly, Patent, Patent law, Outline of patents

AgJunction was also recently granted a new patent in Australia, patent number 2016340745, titled, Steering Controller for Precision Farming.

Key Points: 
  • AgJunction was also recently granted a new patent in Australia, patent number 2016340745, titled, Steering Controller for Precision Farming.
  • We are very pleased to be awarded these three important patents, said Bob Barjesteh, executive vice president and general counsel for AgJunction.
  • AgJunction currently owns or exclusively licenses over 200 precision agriculture patents and pending patents worldwide.
  • Its technologies are critical components in over 30 of the worlds leading precision Ag manufacturers and solution providers and it holds over 200 patents and patents pending.

NeuroSigma Continues to Build a Substantial Global Bioelectronics Patent Portfolio

Retrieved on: 
Friday, March 12, 2021
Monopoly, Patent law, Patent, United States patent law, Outline of patents, Creativity

2821981 entitled Devices, Systems and Methods for Treatment of Medical Disorders; issued January 12, 2021

Key Points: 
  • 2821981 entitled Devices, Systems and Methods for Treatment of Medical Disorders; issued January 12, 2021
    Japanese patent application no.
  • NeuroSigma is the exclusive licensee of the Regent's rights in all TNS-related patents owned by the Regents or co-owned by the Regents and NeuroSigma.
  • Haynes and Boone LLP represented NeuroSigma in the successful prosecution of these patent applications and other related applications.
  • With the addition of the new patents, the broader patent portfolio we have amassed exceeds 50 patents," said Leon Ekchian, Ph.D., NeuroSigma's President and CEO.

PyroGenesis Announces European Patent Office’s Intent to Grant Plasma Atomization (3D Printing) Patent; Increasing Productivity and Further Controlling Particle Size Distribution

Retrieved on: 
Thursday, March 11, 2021
Countries, Government, Law, European Patent Organisation, Patent offices, Monopoly, Patent, European Patent Convention, Outline of patents

Specifically, this patent aims at providing a simplified device geared to increasing productivity while at the same time allowing for further control over particle size distribution, thereby reducing overall costs.

Key Points: 
  • Specifically, this patent aims at providing a simplified device geared to increasing productivity while at the same time allowing for further control over particle size distribution, thereby reducing overall costs.
  • This patent has been filed for patent protection in an additional six different jurisdictions.
  • European patents provide protection not only in the 38 member states of the European Patent Organization, but also in two extension states plus four validation states.
  • This represents an area with approximately 700 million inhabitants1, said Pierre Carabin, Chief Technology Officer of PyroGenesis.